HiberGene Diagnostics, a company focused on the application of molecular technology to infectious disease testing, has completed CE marking of their HG SWIFT instrument.
This simple and easy to use instrument is designed exclusively for use with HiberGene’s growing portfolio of molecular tests for infectious diseases, including the recently launched HG Meningococcus, and the soon to be launched HG GBS, a rapid test for Group B Streptococcus.
The HG SWIFT instrument has a number of advantages over traditional diagnostics platforms. With its small footprint and compact hardware, the system is ideal for labs with space constraints and is also suited for near patient testing.
Simple intuitive software, combined with a touchscreen and wireless communication capability means the HG SWIFT requires minimal training for operators, saving both time and cost. Combined with a low capital cost, it is perfectly positioned for labs where traditional molecular diagnostics, such as PCR, have been out of reach due to the cost and complexity involved.
In addition, by using an isothermal system known as LAMP (Loop Mediated Isothermal Amplification), results are guaranteed to be rapid, taking under an hour, sensitive and specific. Through this, users can ensure faster and more accurate diagnoses, thus improving patient care.
Brendan Farrell, CEO of HiberGene, said: "The HG SWIFT is the instrument of choice for all of HiberGene’s infectious disease tests. When combined with the growing portfolio of molecular tests for infectious diseases developed by HiberGene, the HG SWIFT will become a vital tool in the rapid and accurate diagnosis of infectious diseases and provide significant patient benefits."